Inclusion Criteria:

• * Subjects will be required to satisfy the following criteria at the screening visit unless otherwise stated:
• 1. The patient has provided written informed consent with HIPAA (Health Insurance Portability and Accountability Act) authorization before the initiation of any study-related procedures.
• 2. The patient is at least 18 years of age at the time of consent.
• 3. The patient has an ECOG performance status of Grade 0 - 2
• 4. If of childbearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.
• 5. Subjects will have a BMI of 18 to 49.9 kg/m2, inclusive, at screening.
• 6. Meets clinical criteria described in the groups section above.

Exclusion Criteria:

• * Subjects who meet any of the following criteria will be excluded from the study.
• 1. The patient is pregnant or lactating.
• 2. The patient has participated in another investigational drug study within 3 months prior to Day 1.
• 3. The subject has another significant medical condition requiring active surgical or medical intervention whose urgency would preclude participation in this study (active cardiac or pulmonary conditions,; ongoing ischemia or cardiac symptoms, uncorrected CAD or decompensated CHF).
• 4. The subject has a Hemoglobin A1c\>10.0
• 5. The subject is on greater than 4 anti-hypertensives or has a a systolic blood pressure at time of screening greater than 160mm Hg.
• 6. The patient has a suspected glomerulonephirtis, not including diabetic nephropathy, or hypertensive nephrosclerosis.
• 7. The subject has a history of significant hypersensitivity, intolerance, or allergy to dextran or modified forms of dextran; unless approved by the Investigator.
• 8. The subject has a history or presence of an acutely abnormal ECG, which, in the Investigator's opinion, is clinically significant.
• 9. The subject has exceeded yearly radioactive dose of 30 mSv.
• 10. The subject has a history of drug abuse or alcohol within 2 years before dose administration.
• 11. The subjects used any prescription medications within 14 days prior to Day 1, except as allowed by the inclusion criteria or as deemed acceptable by the Investigator.
• 12. The subject has poor peripheral venous access.
• 13. The subject has donated blood within 30 days prior to Day 1, or plasma within 2 weeks prior to Day 1.
• 14. The subject has received blood products within 2 months prior to Day 1.
• 15. The subject has received any radiopharmaceutical within 7 days prior to the administration of Tc 99m tilmanocept.